Northwest Biotherapeutics, Inc (NWBO) Stock Up After Annual Meeting Results


Shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) are up today after the company released several tidbits of news that took place at their annual shareholder meeting this past Friday.

Most notably, directors Dr. Navid Malik and Linda Powers were re-elected by vote of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) shareholders. Powers won with 82% of the vote, whereas Malik won with 80%. Additionally, Marcum LLC was named the Company’s auditors.

“We greatly appreciate the high turnout and the strong support from our shareholders,” said Linda Powers, CEO. “The support is particularly gratifying after the waves of false and misleading attacks upon the Company and its Directors and Managers personally, in recent months, many of them anonymous. Such attacks divert Company time, attention and resources. Despite this, we remain committed to our mission, and in March, May and September we reported encouraging data from our DCVax-L and DCVax-Direct programs. We also look forward to making more progress in the New Year.”

The stock is up 5.24% or $0.23 following the news, hitting $4.62 per share. About 273,599 shares traded hands. NWBO has declined 46.40% since May 18, 2015 and is downtrending. It has underperformed the S&P500 by 44.13%.

Northwest Biotherapeutics, Inc. is a biotechnology company. The company has a market cap of $408.22 million. The Firm is focused on developing immunotherapy products to treat cancer. It currently has negative earnings. The Company’s platform technology, DCVax, uses activated dendritic cells to mobilize a patient’s own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells.